ABVC BioPharmaABVC
Market Cap: $8.19M
About: ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
38% more funds holding
Funds holding: 8 [Q1] → 11 (+3) [Q2]
0.58% less ownership
Funds ownership: 2.41% [Q1] → 1.83% (-0.58%) [Q2]
49% less capital invested
Capital invested by funds: $333K [Q1] → $171K (-$162K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for ABVC.